Fundraising Overview - The company has been approved to publicly issue convertible bonds with a total face value of RMB 750 million, with a term of 6 years [2] - The actual net amount raised after deducting underwriting fees and other expenses is RMB 733.35 million [2][3] Fund Management - The company has established a special account for the management and use of the raised funds, in compliance with relevant regulations [4] - A tripartite supervision agreement has been signed with multiple banks and the sponsor to ensure the funds are used solely for the "high-end medical consumables industrialization project" [4] Fund Usage and Termination - As of the announcement date, all funds from the special accounts have been fully utilized, and the accounts are no longer in use [7] - The company has decided to terminate the "high-end medical consumables industrialization project" and will use the remaining funds of approximately RMB 358.70 million to permanently supplement working capital [6][7]

Group 1 - The stock of Shangrong Medical (002551) closed at 3.86 yuan on November 27, 2025, with a market capitalization of 3.264 billion yuan, reflecting a 0.26% increase from the previous trading day [1] - The company announced the completion of the public issuance of convertible bonds on February 20, 2019, raising a total of 750 million yuan, with a net amount of 733 million yuan allocated for a "high-end medical consumables industrialization project" [1] - The board and shareholders approved the termination of the project on August 23 and September 12, 2025, with approximately 359 million yuan of the remaining funds being permanently allocated to supplement working capital [1] Group 2 - All funds from the five special accounts for the raised capital have been fully utilized, and the related accounts have been closed, with the tripartite supervision agreement also terminated [1]

Core Viewpoint - Shenzhen Shangrong Medical (002551) announced the termination of the "High-end Medical Consumables Industrialization Project" and plans to use the remaining raised funds to permanently supplement working capital [1][2][3] Group 1: Project Termination - The project was initially approved for a total fundraising of 750 million yuan through convertible bonds, with a net amount of 733 million yuan after expenses [2] - As of July 31, 2025, the project had accumulated an investment of 415 million yuan, representing 56.73% of the planned investment [2] - The decision to terminate the project was influenced by intensified market competition and declining profit margins, making the original profit expectations unattainable [3][4] Group 2: Financial Performance - The company has faced significant financial challenges, with a cumulative loss of nearly 400 million yuan over four and a half years [6] - Revenue figures from 2021 to 2024 were 1.79 billion yuan, 1.28 billion yuan, 1.19 billion yuan, and 1.44 billion yuan, showing a year-on-year decline of -21.04%, -28.74%, -6.49%, and an increase of 21.40% respectively [7] - In the first half of 2025, the company reported a revenue of 528 million yuan, a year-on-year decline of 16.38%, and a net loss of 7.76 million yuan, a significant drop of 155.31% compared to the previous year [7] Group 3: Asset Management and Regulatory Scrutiny - The company has been under regulatory scrutiny regarding the use of raised funds, with questions raised about the project's expected benefits and the authenticity of fund usage [4][5] - As of June 30, 2025, the total assets of the company were 3.542 billion yuan, with cash and cash equivalents amounting to 419 million yuan, a decrease of 17% from the beginning of the period [8]